NCT02013830View on ClinicalTrials.gov

A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Liver Cancer
Interventions
DRUG

bevacizumab [Avastin]

7.5mg/kg iv on day 1 of each 3 week cycle.

DRUG

capecitabine [Xeloda]

1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.

Trial Locations (7)

106

Taipei

114

Taipei

333

Kueishan

3181

Melbourne

169610

Singapore

Unknown

Hong Kong

00112

Taipei

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02013830 - A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer | Biotech Hunter | Biotech Hunter